Skip to main content

Table 1 Patient characteristics at baseline

From: Investigation into cardiac sympathetic innervation during the commencement of haemodialysis in patients with chronic kidney disease

 

Frequency, median (range) or mean ± standard deviation

Gender (number)

 Male

13 (72%)

 Female

5 (28%)

Age (years)

58 ± 18

Medical history (number)

 Hypertension

14 (78%)

 Hypercholesterolemia

6 (33%)

 Diabetes mellitus

6 (33%)

 Smoking

2 (11%)

 Coronary artery disease

0 (0%)

Medication at baseline (number)

 β-blockers

11 (61%)

 ACE ihibitors

6 (33%)

 Diuretics

8 (44%)

Laboratory at inclusion

 Leucocytes (× 109/l)

7.1 (3.3–9.8)

 Haemoglobin (mmol/l)

6.8 (6.0–9.7)

 Trombocytes (× 109/l)

208 (117–347)

 C-reactive protein (mg/l)

0 (0–59)

 Sodium (mmol/l)

140 (135–145)

 Potassium (mmol/l)

4.9 (4.0–5.9)

 Chloride (mmol/l)

107 (98.0–114)

 Urea (mmol/l)

26 (15–38)

 Creatinine (μmol/l)

584 (339–1.31 × 103)

 eGFR (ml/min × 1.73 m2)

8.0 (4.0–12)

 Uric acid (mmol/l)

0.45 (0.23–0.72)

 Calcium (mmol/l)

2.25 (2.07–2.53)

 Phosphate (mmol/l)

1.60 (1.07–2.12)

 Total protein (g/l)

67 (60–77)

 Albumin (g/l)

41 (29–46)

 High-density lipoprotein cholesterol (mmol/l)

1.0 (0.70–2.7)

 Low-density lipoprotein cholesterol (mmol/l)

2.2 (0.80–4.8)

 Glucose (mmol/l)

6.7 (4.1–14)

 Urinary protein excretion (g/24 h)

2.7 (0.40–6.8)

  1. ACE angiotensin converting enzyme, eGFR estimated glomerular filtration rate